In this cross-sectional population-based study, we assessed the incidence of advanced breast cancer based on screening attendance. Women from the Netherlands Cancer Registry were included if aged 49 years and diagnosed with breast cancer between 2006 and 2011, and data were linked with the screening program. Cancers were defined as screen-related (diagnosed <24 months after screening) or nonscreened (all other breast cancers). Two cut-offs were used to define advanced breast cancer: TNM-stage (III-IV vs 0-I-II) and T-stage alone (15 mm vs <15 mm or DCIS). The incidence rates were adjusted for age and logistic regression was used to compare groups. Of the 72,612 included women diagnosed with breast cancer, 44,246 (61%) had screen-related breast cancer. By TNM stage, advanced cancer was almost three times as likely to be at an advanced TNM stage in the nonscreened group compared with the screen-related group (38 and 94 per 100,000, respectively; OR: 2.86, 95%CI: 2.72-3.00). By T-stage, the incidence of advanced cancer was higher overall, and in nonscreened women was significantly higher than in screened women (210 and 169 per 100,000; OR: 1.85, 95%CI: 1.78-1.93). Data on actual screening attendance showed that the incidence of advanced breast cancer was significantly higher in nonscreened women than in screened women, supporting the expectation that screening would cause a stage shift to early detection. Despite critical evaluations of breast cancer screening programs, our data show that breast cancer screening is a valuable tool that can reduce the disease burden in women.
Breast cancer screening aims to reduce breast cancer morbidity and mortality by detecting disease at earlier and more treatable stages. Indeed, trials of breast cancer screening have shown that it can reduce the rate of advanced-stage cancer, and ultimately, reduce the associated mortality. [1] [2] [3] [4] [5] In a meta-analysis of these randomized trials, the associated relative risk reduction was 20%. 6 The strength of these data meant that population-based screening programs were introduced, and subsequent observational studies have confirmed the ability of such programs to reduce mortality. [7] [8] [9] [10] Despite this evidence, however, the contribution of mammographic screening to a reduced rate of advanced-stage breast cancer is still questioned. [11] [12] [13] [14] When introduced, screening should cause a shift in the stage-specific breast cancer incidence, 15 and this should stabilize when screening is fully implemented. Early detection is essential because tumor stage at diagnosis remains important to overall survival. 16, 17 Although lower overall rates of advanced breast cancer in a screened population can indicate the effectiveness of screening, any meaningful study into this association requires that we know whether cancer was diagnosed in a screened or a nonscreened population. To date, however, most observational studies have only reported the incidence of early and advanced breast cancer in all women, without differentiating by screening status. 12, 13, [18] [19] [20] [21] [22] [23] Some recent studies have tried to remedy the failings of existing data by comparing regions with and without screening programs 24 or by classifying women as participants or nonparticipants based on attendance at the first two rounds of screening. 25 However, these approaches use some approximations of screening status, and there is still some uncertainty whether cancer was diagnosed in the screened or the nonscreened women. To the best of our knowledge, only one study has used information about screening attendance at an individual patient level, and this showed a lower rate of advanced disease among screened women. 26 It is important to consider the background incidence of breast cancer when evaluating stage-specific incidence in relation to screening. 27 If the background incidence was increasing, the rate of advanced cancer would also be expected to increase; therefore, if the incidence of advanced cancer was stable in the context of a screening program, one could conclude that a relative reduction in the incidence of advanced cancer existed.
To evaluate the effect of a screening program on the incidence of advanced breast cancer, it is necessary to link data on tumor stage with individual data on screening program attendance. In this study, we compared the age-specific incidence rates of early and advanced breast cancer among attenders and nonattenders of a fully implemented, steadystate, breast cancer screening program. We expected the incidence of advanced breast cancer to remain stable over calendar time in attenders and nonattenders due to the steadystate situation, but to be higher in the nonattenders.
METHODS

Study design
This was a cross-sectional population-based study of women aged 49 years or older diagnosed with breast cancer (invasive and ductal carcinoma in situ) between January 1, 2006, and December 31, 2011. Our focus was on comparing the incidence between women with screen-related breast cancer (screendetected or interval) and those with nonscreened breast cancer. We used data from the Netherlands Cancer Registry (NCR) that were linked to the Netherlands breast cancer screening program. The Central Committee on Research involving Human Subjects determined that this study did not require approval from an ethics committee. The study was approved by the Privacy Review Board of the NCR.
The Netherlands cancer registry
In the Netherlands, all new cases of cancer are registered in the population-based NCR, 28 which has contained data on patient, tumor and treatment characteristics for all in situ and invasive malignancies since 1989. The main source of notification for the NCR is the nationwide network and registry of histo-and cytopathology in the Netherlands (PALGA). After the NCR is notified, registration clerks attend hospitals to collect information on patient and tumor characteristics directly from patient records. Coding in the NCR is based on international rules (i.e., the International Association of Cancer Registries), with TNM staging classified according to the sixth edition until 2009 and the according to the seventh edition thereafter.
29,30
The Netherlands breast cancer screening program 
Study population
Permission for linkage to the NCR was requested for all women when they attended screening, and covered 99.98% of those screened during the study period. 33 
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women who had lobular carcinoma in situ. For women with synchronous breast cancer, only the most advanced cancer was included. In total 72,612 breast cancers were selected.
Definitions
For simplicity, we defined a screen-related group (screendetected or interval cases) and a nonscreened group (never or irregular attenders). Screen-detected and interval cancers included cases diagnosed within 24 months after positive and negative screening results, respectively. All other breast cancers were defined as nonscreened, including those diagnosed in women who never attended screening and in women who were considered to have attended irregularly. The irregular attendance group comprised women who missed an opportunity for screening examination, so had an interval beyond the planned 2 years. When interpreting our results, it should be noted that the terms "screen-related" and "nonscreened" only applied to the 2 years before the date of diagnosis. Age at time of diagnosis was categorized as 49-59, 60-69, 70-74, 75-79, or 80 years, based on an age of 49 years as the official lower limit for screening used by Statistics Netherlands. Age 74 years was the upper age limit for screening, so we included cases of breast cancer diagnosed up to 24 months after screening examination to cover outcomes in this age group. The screened population therefore included women aged 49-76 years. To provide insight in the upper age limit of the screening program, we included patients aged 75-79 years as an extra cutoff point.
Two definitions were used to distinguish advanced from early breast cancer: 1) the TNM classification, with stages III-IV defined as advanced cancer and stages 0-I-II defined as early cancer; 29, 30 and 2) the T-stage alone, with invasive tumor size 15 mm defined as advanced cancer and tumor size <15 mm or ductal carcinoma in situ (regardless of size) defined as early cancer. 34 Breast cancers with an unknown Tstage were excluded from this latter analysis.
Incidence calculations
Breast cancer incidence rates per 100,000 women were calculated separately for the screen-related and nonscreened cancers. To determine the screened population, the number of screened women was obtained directly from data held for the screening program. For each year of diagnosis and age, the number of screened women was calculated by adding the sum of women of a specific age who were screened in a specific calendar year to the number of women 1-year younger and screened in the preceding calendar year. This sum included all women screened in the preceding 24-month period who had the same age in a specific calendar year. Incidence rates per 100,000 screened women were calculated by dividing the total number of screen-related cancers in a specific calendar year by the total number of women screened in that year, before multiplying by 100,000.
When calculating breast cancer incidence in the nonscreened population, the denominator was obtained from data published by Statistics Netherlands. 35 To assess each year of diagnosis, we calculated the total number of women per calendar year as the average of the female population in a given calendar year plus the female population in the year before. To assess specific age ranges, we selected all women of a specific age per calendar year, plus women 1-year younger in the year before. The nonscreened population was then calculated by subtracting the screened population from the total population per year and age. Finally, the nonscreened population was divided into three age groups (49-74, 75-79 and 80 years) and the incidence was calculated per group. We calculated age-specific incidence rates per 100,000 nonscreened women by dividing the total number of nonscreened cancers in a specific calendar year by the population of nonscreened women in that year, before multiplying by 100,000. All rates were reported as age-adjusted European Standardized Rates, with direct standardization based on the 2013 European Standard Population. 36 
Statistical analyses
The incidence rates of advanced-stage cancer in the screened and nonscreened populations were compared by incidence rate ratios (IRR) with 95% confidence intervals (95%CIs). Univariable and multivariable logistic regression analyses were used to estimate differences in advanced stage in cancers diagnosed in women in the screened and nonscreened populations, controlling for age category, year of diagnosis and socioeconomic status (SES). SES was determined based on education, household income and labor market status (based on postal code). Odds ratios (ORs) and 95%CIs were reported. The age category 60-69 years was defined as the reference group to handle the effect of prevalence screening. Breast cancer incidence rates were calculated separately for early and advanced cancer in both classifications (i.e., TNM and T-stage). Sensitivity analyses were performed by 1) excluding women attending the prevalence screening, 2) using a cutoff point of 20 mm for advanced T-stage and 3) including women with previous breast cancer in the 5-year period before diagnosis. Statistical significance was set at a p values of <0.05, and all tests were two-sided. Analyses were performed using the STATA Software Package, Version 14.1 for Windows (Stata Corporation LP, College Station, TX).
RESULTS
The final study cohort included 72,612 women with breast cancer, after excluding women diagnosed with breast cancer in the 5 years before the current diagnosis (n 5 1,757) and women with lobular carcinomas in situ (n 5 478).The screenrelated group included 44,246 cancers (61%), of which 32,158 (73%) were considered screen-detected (Table 1) .
Advanced TNM stage (stages III and IV)
Based on TNM staging, breast cancer was considered advanced in 9.5% and 23% of the screen-related and nonscreened cancers, respectively (p < 0.001) ( Table 1 ). Cancers diagnosed in the screened population were more often TNM stage I, IA, or IB, whereas cancers diagnosed in the nonscreened population were more often stage IIA or higher. Due to an increase in the detection of early stage TNM cancers, the overall incidence of breast cancer increased nonsignificantly from 369 to 408 per 100,000 women between 2006 and 2011 (IRR: 1.11; 95%CI: 0.95-1.27; Fig. 1 , Data Supporting Information Table 2 ). In the screened population, the ageadjusted overall incidence for 2006-2011 was 389/100,000, and the incidence of advanced cancer was 38/100,000 women based on TNM staging (Fig. 2, Data Supporting Information Table 3 ). In eligible nonscreened women (aged 49-74), the overall incidence was similar to that in the screened population (403/ 100,000; p 5 0.619; Table 2 ). By TNM staging, the incidence of Cancer Epidemiology advanced cancer in nonscreened women aged 49-74 (94/ 100,000) was more than double that in screened women (p < 0.001). For nonscreened women just over the age limit for the screening program (aged 75-79), the overall incidence of breast cancer was 287/100,000, consistent with the expected compensatory drop after screening. Beyond age 80 years, the incidence increased again to 390/100,000.
In the multivariable analysis, nonscreened cancers were almost three times more likely than screen-related cancers to be of an advanced TNM stage, with an OR of 2.86 (95%CI: 2.72-3.00; Data Supporting Information Table 4 ). By TNM stage, advanced cancer was diagnosed more often in women aged 49-59 years compared with women aged 60-69 years (OR: 1.07, 95%CI: 1.02-1.13), but less often in women aged 70-74 years (OR: 0.92, 95%CI: 0.85-0.99). Women aged 75-79 and 80 years were not different from the reference category. Also, the chance of being diagnosed with advanced TNM stage cancer was lower with a more recent year of Age-adjusted incidence rates for early and advanced breast cancer based on TNM staging. The incidence rates are reported as European Standardized Rates, and data are shown per year of diagnosis in relation to screening and age. The screened population included women 49-76 years to allow for a 2-year follow-up period after the last screening examination at age 74 years. Tables  5 and 6 ).
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Advanced T-stage (invasive tumors 15 mm)
Among the 72,612 cases, we excluded 7,280 breast cancers with an unknown T-stage (10%), leaving 65,332 cases for the T-stage analysis. Advanced T-stage was diagnosed in 43% of the screened population, compared with 53% in the nonscreened population (p < 0.001; Table 1 ). In screened women, advanced T-stage cancer had an age-adjusted incidence of 169/100,000 (Fig. 3 , Data Supporting Information Table 7 ), which was significantly lower than the incidence of 210/100,000 in nonscreened women (p 5 0.035, Table 2 ). Also, nonscreened women just older than the screening program's age limit (i.e., aged 75-79 years) had a lower overall incidence, but included more than half of all advanced breast cancers (165/100,000 of 287/100,000).
Multivariable analysis demonstrated that advanced T-stage cancers were more likely to be diagnosed in the nonscreened group than in the screen-related group (OR: 1.85, 95%CI:
1.78-1.93; Data Supporting Information Table 8 
DISCUSSION
Based on TNM stage, the incidence of advanced cancer in women who did not attend breast cancer screening was more than double that in women who did attend (94 vs 38 per 100,000; OR: 2.86, 95%CI: 2.72-3.00). Although less prominent, this pattern was still present when using the T-stage classification (OR: 1.85, 95%CI: 1.78-1.93). Moreover, the incidence of advanced-stage breast cancer was stable over calendar time. This was expected given that we studied the Figure 3 . Age-adjusted incidence rates for early and advanced breast cancer based on T-stage alone. The incidence rates are reported as European Standardized Rates, and data are shown per year of diagnosis in relation to screening and age. The screened population included women 49-76 years to allow for a 2-year follow-up period after the last screening examination at age 74 years.
incidence in an established screening program that was in a steady-state phase. These findings are consistent with the screening program's goal to decrease breast cancer morbidity and mortality by detecting the disease earlier.
In this study, the nonscreened cancers included cancers diagnosed in women who were never screened or who attended screening irregularly in the 24 months before diagnosis. This might have caused a lower rate of advanced cancers in the screened population, because these might have been diagnosed in women who attended irregularly and were screened >24 months before (i.e., bias overestimating the effect of screening). However, it is equally possible that early stage cancers were diagnosed shortly after 24 months, which would have underestimated the effect of screening with the rate of early stage cancer increasing in the nonscreened population. Unfortunately, the extent of each bias is unknown in this study.
When studying the effect of screening attendance on cancer stage, it is essential to know whether cancers are diagnosed in screened or nonscreened women. This observational study is among the first to have used actual screening attendance to compare the incidence of advanced breast cancer based on actual screening status. Our results corroborate the results of most randomized trials, which have shown that screening results in a decrease in the rate of advanced-stage cancer. [1] [2] [3] [4] [5] Observational studies have also looked for possible changes in the incidence of advanced-stage cancer after introducing a screening program; although early stage disease tends to have increased in these studies, advanced stage disease has variously been shown to decrease significantly, [20] [21] [22] 37 slightly, 12, 18 or not at all. 23, 24, 38 However, none of these studies has been able to link tumor stage to actual attendance at the individual patient level, and have instead relied on approximations. This lack of information on actual attendance means that tumors could have been detected in eligible nonattenders outside the screening program.
In an observational study, Puliti et al. tried to allocate tumors by screening attendance (i.e., as screened and nonscreened women) based on attendance at the first two screening rounds. Consistent with our results and those of their previous study, 20 they described a higher incidence of advanced stage cancers in nonscreened women. 24 Our review of the literature only revealed one study that used information about individual screening attendance, and this showed a lower incidence of advanced-stage disease among screened women. 26 It is difficult to compare our results with those of previous studies because we allocated tumors based on the actual attendance of each woman, which is a unique strength of our study.
Moreover, none of these studies corrected for a possible annual increase in the background incidence. Several reports have shown that the background incidence of breast cancer increased for several decades before the introduction of screening, with evidence showing that it was expected to increase further. 27, 39 This increase might have resulted from an aging population, increased exposure to risk factors, or both. 27 Earlier studies, which showed that screening only reduced the rate of advanced stage disease slightly, were premised on the potentially erroneous basis that there would be no increase in background incidence. 13, 18, 22 Given the preceding epidemiological trends, and assuming an increase in the underlying incidence of breast cancer, a stable incidence of advanced cancer could be interpreted as a relative reduction. We contend that failing to take this into consideration could underestimate the effect of screening. In the present study, we reported data for a period in which the screening program was well established, reflecting a steady-state situation, so we did not expect to observe the changes in incidence that would normally be expected to accompany the implementation of a screening program. Nevertheless, we did find a slight but nonsignificant increase in the incidence of early stage cancer, possibly due to an increase in the background incidence.
It is likely that screening resulted in overdiagnosis by detecting cases of breast cancer (ductal carcinoma in situ or invasive carcinoma) that may not have presented clinically during a woman's lifetime. 27 The likely extent of overdiagnosis is unclear, but previous studies have given estimates that range from 0% to 52%. 12, [40] [41] [42] The increase in early stage breast cancer might also be caused by the higher detection ability of digital mammography during the latter study period. If present, one would expect overdiagnosis to cause a higher overall incidence in screened women compared with nonscreened women, yet rates were similar throughout the study period (389 and 403 per 100,000, respectively; p 5 0.619).
Among those aged 75-79 years, the incidence was low compared with younger age groups. This can be explained by the so-called compensatory drop: for example, due to the lead-time, an initial increase in incidence among screened women is followed by a decrease among older women who are no longer offered screening. 43 Compared with the reference category, the youngest age category (i.e., 49-59 years) had a higher incidence of advanced-stage disease in the multivariable analysis, possibly because of cancers diagnosed in the prevalence screening. However, similar results were shown in a sensitivity analysis that excluded women who underwent an initial screening examination. Despite the higher incidence in the youngest age category, the incidence of advanced breast cancer remained stable over time.
The steady-state of the screening program meant that not only the number but also the age distribution of women invited and screened for the first time was relatively stable. The incidence of advanced cancer was also stable. An earlier study showed a significant decrease in advanced breast cancer in the former target age group (i.e., 50-69 years) after the Dutch screening program was introduced, with a concomitant increase in these tumors among women in younger and older age categories. 22 At that time, however, it was not possible to determine the participation status at an individual
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level. The steady state of the screening program and lack of major changes to screening policy after 2001 meant that we did not expect a further decrease in the incidence of advanced breast cancer during our study.
A major strength of this study is that we classified breast cancers as screen-related (screen-detected or interval) and nonscreened (never or irregular attenders). We also calculated the incidence rates for early and advanced breast cancer based on staging by both the TNM classification and tumor size alone. The finding that rates of advanced cancer were lower by TNM stage (including information on lymph node and distant metastasis) compared with T-stage alone is important because the TNM stage determines clinical treatment, with less advanced TNM stages associated with less treatment burden. However, knowing that the relationship was still valid for advanced cancers based on tumor size alone is relevant because screening relies on the detection of lesions that are visible on mammography. Our cutoff point of 15 mm for advanced T-stage disease was based on previous research, 34, 44 and produced results that were similar to those obtained with a cutoff point of 20 mm (Data Supporting Information, Tables 11 and 12 ). To ensure that we used a clean definition for the relation to screening, without interference from hospital check-ups, we included all first cancers and any second cancers diagnosed at least 5 years after a first breast cancer. This will have led to a slightly lower overall incidence of breast cancer compared with the actual incidence which includes second breast cancers as well. However, sensitivity analyses produced similar results when including all breast cancers (Data Supporting Information Tables 13  and 14) .
A limitation of this study is that we had no information about women with a higher than average risk for breast cancer (e.g., those with a BRCA1/2 mutation or a high familial risk), so we cannot exclude the possibility that these women did not attend screening. However, to reduce the potential influence of this group, women younger than 49 years were excluded. A systematic review has also shown that there is no difference in the proportions of advanced stage cancers between carriers and noncarriers of the BRCA1/2 mutation. 45 Another issue is that participation in the screening program was voluntary, which meant that several factors may have influenced attendance; in particular, it is known that women with a low SES have lower attendance rates. 46 Given that women with a low SES were more likely to be diagnosed with advanced cancer in this study, we corrected for SES in the multivariable analysis. Furthermore, another study has shown that the overall influence of bias due to self-selection was minor on the effectiveness of the Netherlands screening program. 47 The exact tumor size was unknown in 10% of cases, with the highest unknown proportion in women aged 80 years. From 2010 onwards, this proportion decreased rapidly, with a shift toward early T-stage disease, probably reflecting the fact that older women now receive more specific diagnostic work-ups. There was also no information about breast density, which is important because a dense breast increases the risk of breast cancer and reduces mammographic detectability. 48, 49 However, the inclusion of mostly postmenopausal women meant that breast density was probably not a major confounder for the differences in stage. 50 Finally, it should be noted that we estimated the nonscreened population based on the screened and overall populations, which may have led to a small margin of error.
In conclusion, data based on actual screening attendance showed that the incidence of advanced breast cancer was significantly higher in nonscreened women compared with screened women. Our results support the expectation that screening would cause a stage shift to the detection of breast cancer at an earlier stage, making it possible to reduce morbidity and mortality associated with breast cancer. Despite critical evaluations of breast cancer screening programs in other studies, our data show that breast cancer screening is a valuable tool that can reduce the disease burden in women.
